Back to Journals » Infection and Drug Resistance » Volume 11

Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities

Authors Asif M, Alvi IA, Rehman SU

Received 27 February 2018

Accepted for publication 20 April 2018

Published 21 August 2018 Volume 2018:11 Pages 1249—1260


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Suresh Antony

Muhammad Asif,1,2 Iqbal Ahmad Alvi,1,3 Shafiq Ur Rehman1

1Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan; 2Department of Pathology, King Edward Medical University, Lahore, Pakistan; 3Department of Microbiology, Hazara University, Mansehra, Pakistan

Abstract: Acinetobacter baumannii, once considered a low-category pathogen, has emerged as an obstinate infectious agent. The scientific community is paying more attention to this pathogen due to its stubbornness to last resort antimicrobials, including carbapenems, colistin, and tigecycline, its high prevalence of infections in the hospital setting, and significantly increased rate of community-acquired infections by this organism over the past decade. It has given the fear of pre-antibiotic era to the world. To further enhance our understanding about this pathogen, in this review, we discuss its taxonomy, pathogenesis, current treatment options, global resistance rates, mechanisms of its resistance against various groups of antimicrobials, and future therapeutics.

Keywords: antibiotic resistance, colistin, tigecycline, phage therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]